The Limited Times

Now you can see non-English news...

Beyfortus, the false start of the new treatment for bronchiolitis

2023-12-04T07:55:40.369Z

Highlights: Beyfortus, the new treatment for bronchiolitis, arrived in France on September 15, 2023. The government had ordered 200,000 doses to last until the end of the winter. The effectiveness of treatment against infections in general appeared clearly in clinical trials. But the effectiveness against severe forms, and therefore hospitalizations of toddlers, was more unclear. It will be necessary to wait until mid-December for the first "real-life" results to be published. The French National Authority for Health (HAS) spoke of "heterogeneous results that reflect uncertainties"


Nirsevimab, a preventive drug that French children had to be the first to have at their disposal to protect themselves from respiratory infections


It was announced as a first and a "major breakthrough", according to the Minister of Health. Beyfortus, the very first preventive treatment against RSV, the virus that causes bronchiolitis, arrived in France on September 15, 2023, with a double promise: to be quickly accessible to all children under 6 months, and to protect them throughout the bronchiolitis season.

Two months later, this preventive treatment based on a single injection of antibodies, available in two forms, 50 mg and 100 mg, has not yet caused the hoped-for revolution. And yet, the French rushed to it!

'Heterogeneous results' and 'uncertainties'

The government, which had ordered 200,000 doses to last until the end of the winter, quickly had to reserve it only for maternity wards, and procured an additional 50,000 doses, 30,000 for maternity wards and 20,000 to cover unfulfilled orders in pharmacies in September.

"We will contact pharmacists again to confirm the number of doses they have not been able to dispense in order to give them to them in early December," a Sanofi spokesperson said.

Read alsoBronchiolitis: after the lack of doses, the vagueness of the effectiveness of the preventive treatment Beyfortus?

Is the treatment not very accessible, but is it at least effective? It will be necessary to wait until mid-December for the first "real-life" results to be published. They are eagerly awaited, because while the effectiveness of treatment against infections in general appeared clearly in clinical trials, the effectiveness against severe forms, and therefore hospitalizations of toddlers, was more unclear.

The French National Authority for Health (HAS), the body responsible for evaluating a new treatment, spoke of "heterogeneous results that reflect uncertainties on this criterion of major clinical interest".

Source: leparis

All life articles on 2023-12-04

You may like

Trends 24h

Life/Entertain 2024-02-27T10:04:13.714Z
Life/Entertain 2024-02-27T05:15:30.051Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.